TepeGZellerTAlbrechtT. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.
2.
WerkMLangnerSReinkensmeierB. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.
3.
WerkMAlbrechtTMeyerDR. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.
4.
MicariACioppaAVadalaG. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. J Am Coll Cardiol Interv. 2013;6:282–289.
5.
ScheinertDDudaSZellerT. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.
6.
RosenfieldKJaffMRWhiteCJ. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
7.
LairdJRSchneiderPATepeG. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
8.
TepeGLairdJSchneiderP. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
9.
ScheinertDSchmidtAZellerT. German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther. 2016;23:409–416.
10.
SchroederHMeyerDRLuxB. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86:278–286.
11.
ScheinertDSchulteKLZellerT. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
12.
SalisburyACLiHVilainKR. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9:2343–2352.
13.
BausbackYWillfort-EhringerASievertH. Six-month results from the initial randomized study of the Ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24:459–467.
14.
DiamantopoulosAGuptaYZayedH. Paclitaxel-coated balloons and aneurysm formation in peripheral vessels. J Vasc Surg. 2015;62:1320–1322.
15.
GranadaJFStenoienMBuszmanPP. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1:e000117.
16.
GongoraCAShibuyaMWesslerJD. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015;8:1115–1123.
17.
SchmidtAPiorkowskiMGornerH. Drug-coated balloons for complex femoropopliteal lesions: two year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
18.
SteinerSSchmidtABausbackY. Midterm patency after femoropopliteal interventions: a comparison of standard and interwoven nitinol stents and drug-coated balloons in a single-center, propensity score-matched analysis. J Endovasc Ther. 2016;23:347–355.
19.
FanelliFCannavaleAGazzettiM. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
20.
FoleyTRCotterRPKokkinidisDG. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease [published online March15, 2017]. Catheter Cardiovasc Interv. doi:10.1002/ccd.26984.
21.
MicariAVadalaGCastriotaF. 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2016;9:950–956.
